Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron Pharmaceuticals, Inc.'s stock has dropped 30% since July due to concerns around Eylea's declining market share in the face of competition from generics and Roche's Vabysmo. Dupixent's ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.6% after a judge denied the company's motion for a preliminary injunction to block an Amgen (AMGN) biosimilar version of Regeneron's blockbuster ...

Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth. Mammoth Biosciences, that is. The companies will collaborate on in vivo CRISPR-based gene editing ...

George Yancopoulos is in touch with his teenage self. After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once ...

Regeneron has brought its bispecific antibody odronextamab through another test, presenting updated data on the lymphoma candidate ahead of an FDA approval decision scheduled for March. The data ...

Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing ...

Regeneron Pharmaceuticals Inc. announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s stake in the Regeneron-Sanofi collaboration on cancer ...

Amgen reported sales of $1.117 billion for Repatha last year, which represented a 26% increase from 2020. Meanwhile, Regeneron registered sales of Praluent at $170 million, a 13% increase from ...